Stoke Therapeutics (NASDAQ:STOK) Price Target Lowered to $58.00 at Canaccord Genuity Group

Stoke Therapeutics (NASDAQ:STOK) had its target price cut by equities researchers at Canaccord Genuity Group from $60.00 to $58.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target indicates a potential upside of 96.21% from the stock’s current price.

Several other analysts also recently weighed in on STOK. Weiss Ratings downgraded Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Chardan Capital restated a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Tuesday. BTIG Research reiterated a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a report on Monday, May 11th. Finally, The Goldman Sachs Group began coverage on shares of Stoke Therapeutics in a research report on Monday, July 13th. They set a “buy” rating and a $44.00 price target for the company. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $42.83.

Stoke Therapeutics Trading Up 2.4%

NASDAQ STOK opened at $29.56 on Tuesday. Stoke Therapeutics has a 1-year low of $12.71 and a 1-year high of $40.22. The stock has a 50-day moving average of $30.39 and a 200-day moving average of $32.00. The firm has a market cap of $1.84 billion, a PE ratio of -10.52 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. The company had revenue of $9.32 million for the quarter, compared to analysts’ expectations of $4.89 million. As a group, equities research analysts forecast that Stoke Therapeutics will post -3.22 earnings per share for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In other news, insider Barry Ticho sold 1,795 shares of Stoke Therapeutics stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $30.58, for a total transaction of $54,891.10. Following the sale, the insider owned 34,826 shares of the company’s stock, valued at approximately $1,064,979.08. The trade was a 4.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total transaction of $43,637.15. Following the transaction, the general counsel owned 18,086 shares in the company, valued at $541,675.70. This represents a 7.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Hussman Strategic Advisors Inc. purchased a new position in shares of Stoke Therapeutics in the 4th quarter valued at approximately $2,000,000. Baillie Gifford & Co. purchased a new stake in Stoke Therapeutics in the fourth quarter worth $7,837,000. Candriam S.C.A. raised its holdings in Stoke Therapeutics by 12.4% in the first quarter. Candriam S.C.A. now owns 502,020 shares of the company’s stock worth $16,346,000 after purchasing an additional 55,330 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Stoke Therapeutics by 11.2% in the first quarter. Janus Henderson Group PLC now owns 1,612,781 shares of the company’s stock worth $52,456,000 after purchasing an additional 161,848 shares in the last quarter. Finally, Privium Fund Management B.V. purchased a new position in Stoke Therapeutics during the fourth quarter valued at $1,746,000.

Stoke Therapeutics News Summary

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Chardan Capital reaffirmed its “Buy” rating and assigned a $35 price target, implying approximately 18% upside from the referenced $29.56 level. This provides a positive analyst catalyst for STOK. Benzinga analyst rating report
• Positive Sentiment: Second-quarter revenue was about $9.3 million, well above the $4.89 million consensus estimate. The result suggests stronger-than-anticipated revenue generation and may help offset concerns about the company’s ongoing cash burn. Zacks second-quarter earnings report
• Neutral Sentiment: Management provided business updates on zorevunersen, Stoke’s lead investigational RNA medicine and potential disease-modifying treatment for Dravet syndrome, including progress in its global development program. Investors are likely focused on clinical execution and future regulatory milestones. Stoke Therapeutics second-quarter business update
• Neutral Sentiment: Brokerages collectively rate STOK “Moderate Buy,” indicating generally favorable but not uniformly bullish expectations. Brokerage recommendation report
• Negative Sentiment: Stoke reported a quarterly loss of $0.93 per share, missing estimates of roughly $0.80–$0.82 and widening from a $0.40 loss a year earlier. Its negative net margin and return on equity underscore continued substantial operating losses. Stoke Therapeutics earnings report

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.